Allison August
Company: Moderna
Job title: VP, Clinical Development, Infectious Diseases
Seminars:
Lipid-Encapsulated mRNA Delivery of a Monoclonal Antibody with Neutralizing Activity Against Chikungunya Virus: Results From a Phase 1 Trial 2:15 pm
day: Day One
Panel Discussion 5:00 pm
day: Day One
Lipid-Encapsulated mRNA Delivery of a Monoclonal Antibody with Neutralizing Activity Against Chikungunya Virus: Results From a Phase 1 Trial 2:15 pm
This phase 1, first-in-human, randomized, placebo-controlled, proof-ofconcept trial conducted from January 2019 to June 2020 evaluated the safety and pharmacology of mRNA-1944, a lipid nanoparticle-encapsulated messenger RNA encoding the heavy and light chains of a CHIKV-specific monoclonal neutralizing antibody, CHKV-24 (NCT03829384) The primary outcome was to evaluate the safety and tolerability of escalating doses of…Read more
day: Day One
Panel Discussion 5:00 pm
With mRNA- based vaccines now established for certain infectious diseases, it is now important to realise the opportunities of such mRNA- based vaccine therapeutic applications and the surrounding regulatory requirements. From development to commercialization, we will explore aspects of mRNA- based vaccines beyond Sars-COVID-19. What does the future look like for the next generation of…Read more
day: Day One